Arq Shares Plunge 46% After Disappointing Q4 Loss and Weak 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ARQ?
Source: seekingalpha
- Quarterly Loss Report: Arq reported a GAAP loss per share of $1.20 for Q4 2025, missing analyst estimates by $1.14, which led to a significant drop in stock price, indicating market concerns over the company's profitability.
- Modest Revenue Growth: Although revenue increased by 8.7% year-over-year to $29.4 million, slightly exceeding consensus estimates by $0.81 million, profitability weakened considerably as adjusted EBITDA fell to $0.3 million from $3.8 million a year earlier, highlighting increased cost pressures.
- Weak 2026 Guidance: The company issued its first detailed financial guidance for 2026, projecting revenue between $120 million and $125 million, well below the consensus estimate of $136.9 million, indicating uncertainty in future growth prospects.
- Investor Confidence Shaken: The disappointing outlook has rattled investors, causing Arq's stock to plummet sharply following the announcement, reflecting concerns over the company's financial health and potentially impacting its long-term financing capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARQ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARQ
Wall Street analysts forecast ARQ stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.200
Low
7.50
Averages
7.75
High
8.00
Current: 3.200
Low
7.50
Averages
7.75
High
8.00
About ARQ
Arq, Inc. is a diversified environmental technology. The Company is a vertically integrated producer of activated carbon products in North America. It is engaged in the sale of consumable air, water, and soil treatment solutions, primarily based on activated carbon (AC). It manufactures and sells AC and other chemicals used to capture and remove impurities, contaminants and pollutants for the coal-fired power generation, industrial, water treatment, and water and soil remediation markets, which it collectively refers to as the advanced purification technologies (APT) market. Its AC products include both powdered activated carbon and granular activated carbon. It also owns the Five Forks Mine, a lignite coal mine that supplies the primary raw material for the manufacturing of its products. Its products are used to purify contaminated liquid, soil, and gas streams from a variety of industrial sources, including wastewater treatment plants, coal-fired power plants and other end markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arq Shares Plunge 46% After Disappointing Q4 Loss and Weak 2026 Guidance
- Quarterly Loss Report: Arq reported a GAAP loss per share of $1.20 for Q4 2025, missing analyst estimates by $1.14, which led to a significant drop in stock price, indicating market concerns over the company's profitability.
- Modest Revenue Growth: Although revenue increased by 8.7% year-over-year to $29.4 million, slightly exceeding consensus estimates by $0.81 million, profitability weakened considerably as adjusted EBITDA fell to $0.3 million from $3.8 million a year earlier, highlighting increased cost pressures.
- Weak 2026 Guidance: The company issued its first detailed financial guidance for 2026, projecting revenue between $120 million and $125 million, well below the consensus estimate of $136.9 million, indicating uncertainty in future growth prospects.
- Investor Confidence Shaken: The disappointing outlook has rattled investors, causing Arq's stock to plummet sharply following the announcement, reflecting concerns over the company's financial health and potentially impacting its long-term financing capabilities.
See More
Arq, Inc. Under Investigation for Potential Investor Claims
- Production Halt Impact: On March 9, 2026, Arq, Inc. announced a pause in operations at its Corbin, Kentucky granular activated carbon (GAC) facility, limiting annual production capacity to approximately 15 million pounds, which directly affects the company's revenue and market confidence.
- Financial Loss Disclosure: The company recorded a $44.8 million impairment charge, reflecting significant financial losses related to the GAC project, potentially exposing the company to greater investor losses and legal liabilities.
- Litigation Risk: Arq is engaged in litigation with the engineering consultant responsible for the plant's design, which not only increases the company's legal risks but may also further delay the resumption of the GAC project, impacting future financial performance.
- Adjusted Financial Outlook: The company's 2026 financial guidance excludes contributions from the GAC initiative, projecting revenues between $120 million and $125 million and adjusted EBITDA between $17 million and $20 million, indicating a growing reliance on its PAC business that may affect investor confidence.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Arq Reports Q4 2025 Financial Results with Mixed Earnings Guidance
- Earnings Report: Arq's Q4 2025 GAAP EPS of -$1.20 misses by $1.14, indicating challenges in profitability; however, revenue of $29.4 million, up 8.7% year-over-year, beats expectations by $0.81 million, suggesting ongoing sales momentum.
- Adjusted EBITDA Decline: The adjusted EBITDA for Q4 stands at $0.3 million, significantly down from $3.8 million in the prior year, reflecting cost pressures and declining operational efficiency, which may impact future investor confidence.
- Financial Guidance: For the first time, Arq provides detailed guidance for FY 2026, expecting revenue between $120 million and $125 million, below the consensus of $136.94 million, indicating a cautious outlook on future growth, while adjusted EBITDA is projected at $17-20 million.
- Operational Metrics: The company discloses expected PAC average selling price of $0.88 to $0.91 per pound and production volumes projected at 122-125 million pounds, indicating stability in pricing and production capacity despite market challenges.
See More
Arq, Inc. Reports Q4 Loss of $50.03 Million
- Financial Overview: Arq, Inc. reported a Q4 loss of $50.03 million, translating to a loss of $1.20 per share, which is a significant deterioration from last year's loss of $1.34 million or $0.03 per share, indicating increased financial pressure on the company.
- Revenue Growth: Despite the worsening losses, the company saw an 8.8% year-over-year revenue increase in Q4, reaching $29.43 million compared to $27.04 million last year, suggesting that Arq still possesses some sales capability in the market.
- Earnings Per Share Comparison: Arq's EPS dropped from -$0.03 to -$1.20 compared to last year, reflecting significant challenges in cost control and profitability enhancement, which may impact investor confidence.
- Overall Financial Health: The earnings report indicates that while revenue is growing, the ongoing losses could raise concerns among investors regarding the company's future sustainability, potentially affecting its stock performance and market trust.
See More
Arq Reports 9% Revenue Growth in Q4, But Net Loss Widens
- Revenue Growth: Arq reported total revenue of $29.4 million for Q4 2025, reflecting a 9% increase driven primarily by enhanced volumes and pricing, although overall profitability was impacted by rising costs.
- Widening Net Loss: The company recorded a net loss of $52.6 million for FY 2025, a significant increase from a net loss of $5.1 million in FY 2024, with Q4 net loss reaching $50 million compared to $1.3 million in Q4 2024.
- GAC Production Pause: Arq has decided to pause GAC production to conduct a comprehensive engineering and production process optimization review, addressing current thermal oxidizer capacity limitations, which can only support 15 million pounds annually, far below the target of 25 million pounds.
- Executive Change: The company announced that CFO Jay Voncannon is leaving immediately, with Stacia Hansen stepping in as principal financial officer while continuing her role as Chief Accounting Officer, a leadership change that may impact future financial strategies.
See More
Arq Shares Plunge 46% After Disappointing Q4 Loss and Weak 2026 Guidance
- Quarterly Loss Report: Arq reported a GAAP loss per share of $1.20 for Q4 2025, missing analyst estimates by $1.14, which led to a significant drop in stock price, indicating market concerns over the company's profitability.
- Modest Revenue Growth: Although revenue increased by 8.7% year-over-year to $29.4 million, slightly exceeding consensus estimates by $0.81 million, profitability weakened considerably as adjusted EBITDA fell to $0.3 million from $3.8 million a year earlier, highlighting increased cost pressures.
- Weak 2026 Guidance: The company issued its first detailed financial guidance for 2026, projecting revenue between $120 million and $125 million, well below the consensus estimate of $136.9 million, indicating uncertainty in future growth prospects.
- Investor Confidence Shaken: The disappointing outlook has rattled investors, causing Arq's stock to plummet sharply following the announcement, reflecting concerns over the company's financial health and potentially impacting its long-term financing capabilities.
See More
Arq, Inc. Under Investigation for Potential Investor Claims
- Production Halt Impact: On March 9, 2026, Arq, Inc. announced a pause in operations at its Corbin, Kentucky granular activated carbon (GAC) facility, limiting annual production capacity to approximately 15 million pounds, which directly affects the company's revenue and market confidence.
- Financial Loss Disclosure: The company recorded a $44.8 million impairment charge, reflecting significant financial losses related to the GAC project, potentially exposing the company to greater investor losses and legal liabilities.
- Litigation Risk: Arq is engaged in litigation with the engineering consultant responsible for the plant's design, which not only increases the company's legal risks but may also further delay the resumption of the GAC project, impacting future financial performance.
- Adjusted Financial Outlook: The company's 2026 financial guidance excludes contributions from the GAC initiative, projecting revenues between $120 million and $125 million and adjusted EBITDA between $17 million and $20 million, indicating a growing reliance on its PAC business that may affect investor confidence.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Arq Reports Q4 2025 Financial Results with Mixed Earnings Guidance
- Earnings Report: Arq's Q4 2025 GAAP EPS of -$1.20 misses by $1.14, indicating challenges in profitability; however, revenue of $29.4 million, up 8.7% year-over-year, beats expectations by $0.81 million, suggesting ongoing sales momentum.
- Adjusted EBITDA Decline: The adjusted EBITDA for Q4 stands at $0.3 million, significantly down from $3.8 million in the prior year, reflecting cost pressures and declining operational efficiency, which may impact future investor confidence.
- Financial Guidance: For the first time, Arq provides detailed guidance for FY 2026, expecting revenue between $120 million and $125 million, below the consensus of $136.94 million, indicating a cautious outlook on future growth, while adjusted EBITDA is projected at $17-20 million.
- Operational Metrics: The company discloses expected PAC average selling price of $0.88 to $0.91 per pound and production volumes projected at 122-125 million pounds, indicating stability in pricing and production capacity despite market challenges.
See More
Arq, Inc. Reports Q4 Loss of $50.03 Million
- Financial Overview: Arq, Inc. reported a Q4 loss of $50.03 million, translating to a loss of $1.20 per share, which is a significant deterioration from last year's loss of $1.34 million or $0.03 per share, indicating increased financial pressure on the company.
- Revenue Growth: Despite the worsening losses, the company saw an 8.8% year-over-year revenue increase in Q4, reaching $29.43 million compared to $27.04 million last year, suggesting that Arq still possesses some sales capability in the market.
- Earnings Per Share Comparison: Arq's EPS dropped from -$0.03 to -$1.20 compared to last year, reflecting significant challenges in cost control and profitability enhancement, which may impact investor confidence.
- Overall Financial Health: The earnings report indicates that while revenue is growing, the ongoing losses could raise concerns among investors regarding the company's future sustainability, potentially affecting its stock performance and market trust.
See More
Arq Reports 9% Revenue Growth in Q4, But Net Loss Widens
- Revenue Growth: Arq reported total revenue of $29.4 million for Q4 2025, reflecting a 9% increase driven primarily by enhanced volumes and pricing, although overall profitability was impacted by rising costs.
- Widening Net Loss: The company recorded a net loss of $52.6 million for FY 2025, a significant increase from a net loss of $5.1 million in FY 2024, with Q4 net loss reaching $50 million compared to $1.3 million in Q4 2024.
- GAC Production Pause: Arq has decided to pause GAC production to conduct a comprehensive engineering and production process optimization review, addressing current thermal oxidizer capacity limitations, which can only support 15 million pounds annually, far below the target of 25 million pounds.
- Executive Change: The company announced that CFO Jay Voncannon is leaving immediately, with Stacia Hansen stepping in as principal financial officer while continuing her role as Chief Accounting Officer, a leadership change that may impact future financial strategies.
See More
